Recent clinical trial reports have demonstrated that RHB-104 has shown a consequential improvement in CD biomarkers of inflammation such as C-reactive protein (CRP) and Crohn’s disease activity index (CDAI) with or without concomitant anti-TNF-α or immunosuppressive therapy [17]. This evidence concerns the gene TNF and Crohn disease.